Cabot

A report states that long-acting cabotegravir/rilpivirine, an injectable two-drug regimen given less frequently than daily pills, is superior to daily oral antiretroviral therapy for treating HIV. If confirmed in clinical data, the finding could mark a shift in how HIV maintenance treatment is delivered, offering patients an alternative to strict daily adherence regimens.